Cellectis (CLLS)

• Market cap: $119M
• 1 day: -6.35%
• 5 days: -16.9%
• 1 month: -35.52%
• 3 months: -59.31%
• 6 months: -72.43%
• Year to date: -75.42%
• 1 year: -73.3%
• 5 years: -87.1%
• 10 years: -94.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229